Further investigation has revealed that CB can powerfully reverse EBV-miR-BART22-induced cisplatin resistance via upregulating MAP2K4 to antagonize Myh9/GSK3β/β-catenin and its downstream tumor stemness and EMT signals in nasopharyngeal carcinoma. This evidence concerns the gene MAP2K4 and neoplasm.